Novartis AG
- NVS
- NYSE
- Drug manufacturers
- Innovative Medicines
- Oncology/Immunology
$150.21
Today −0.27%Quote Oct 19, 2026, 07:39 PM UTC
+6.88%over the last month
Max drawdown −4.1%From 1-month high 0.0%3 months +0.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Novartis
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies.
Where the money comes from
Q2 2023 revenue $11.24B
- Top 20 products$8.79B78.2%
- Rest of portfolio$2.45B21.8%
Sector
Healthcare
Industry
Drug manufacturers
Exchange
NYSE
Employees
75,267
Market value
$285.51B
Quote Oct 19
Floor
$147.42
1.9% below price
Resistance
$150.55
0.2% above price
Price vs analyst targets
25 analysts
Lowest target
$136.00Highest target
$156.00
$136.00Highest target
$156.00
- Price $150.21
- Average target $146.00
- Analysts' target range
Analysts' average target sits about 3% lower.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NVSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free